Related Experiment Video
Updated: Aug 7, 2026
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
Suppression of rhabdomyosarcoma growth by fumagillin analog TNP-470
T Kalebic1, M Tsokos, L J Helman
1Molecular Oncology Section, Pediatric Branch, National Cancer Institute, Bethesda, MD 20892, USA.
Abstract:
The purpose of our study was to investigate a novel therapeutic approach for rhabdomyosarcoma (RMS) in an animal model. The pursuit of new therapeutic modalities for RMS is critically important since this type of tumor is the most common soft tissue sarcoma in children and because patients with metastatic disease may not be cured with current therapeutic modalities. We studied whether RMS growth may be suppressed by TNP-470, an analog of fumagillin, which was found to inhibit neoangiogenesis. Our data had shown that animals treated with TNP-470 (60 mg/kg), over a specific period of time, had approximately 50% smaller tumors than controls. Consistent with previous observations, treatment with TNP-470 decreases the level of the cyclin D1. Tumors dissected from TNP-470-treated animals had also considerable necrotic areas. In addition, TNP-470 had a direct cytotoxic effect on RMS cells in vitro. Our study has shown, therefore, that RMS in an animal model and in vitro responds to treatment with TNP-470, which suggests that the inhibitors of angiogenesis may be useful in a novel therapeutic design for RMS.
Insights
This study explored TNP-470, an angiogenesis inhibitor, as a novel therapy for rhabdomyosarcoma (RMS). TNP-470 significantly reduced tumor size in an animal model and showed direct cytotoxicity against RMS cells.
Area of Science:
- Oncology
- Pharmacology
- Cancer Biology
Background:
- Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma.
- Metastatic RMS often has a poor prognosis with current treatments.
- Novel therapeutic strategies are crucial for improving RMS patient outcomes.
Purpose of the Study:
- To investigate TNP-470, an angiogenesis inhibitor, as a potential treatment for RMS.
- To evaluate the efficacy of TNP-470 in suppressing RMS tumor growth in an animal model.
- To assess the direct effects of TNP-470 on RMS cells in vitro.
Main Methods:
- Treatment of RMS-bearing animals with TNP-470 (60 mg/kg).
- Assessment of tumor size reduction and histological analysis for necrosis.
- In vitro studies to determine the cytotoxic effects of TNP-470 on RMS cells.
- Measurement of cyclin D1 levels in tumors.
Main Results:
- TNP-470 treatment resulted in approximately 50% smaller tumors compared to controls.
- Tumors from TNP-470 treated animals exhibited significant necrotic areas.
- TNP-470 demonstrated a direct cytotoxic effect on RMS cells in vitro.
- Cyclin D1 levels were decreased following TNP-470 treatment.
Conclusions:
- TNP-470 effectively suppresses RMS growth in an animal model.
- TNP-470 exhibits direct anti-cancer activity against RMS cells.
- Angiogenesis inhibitors, such as TNP-470, represent a promising therapeutic avenue for RMS.
More Related Videos
08:19Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
13:41Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
Published on: January 13, 2023